[4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto

A salt having the formula:

• in a crystalline solid form C characterized by at least one of:
• (i) an X-ray powder diffraction pattern substantially in accordance with FIG. 15;
• and
• (ii) a DSC scan substantially in accordance with the DSC pattern shown in FIG. 20.

A salt having the formula:

• in a crystalline solid form D characterized by at least one of:
• (i) an X-ray powder diffraction pattern substantially in accordance with FIG. 21;
• and
• (ii) a DSC scan substantially in accordance with the DSC pattern shown in FIG. 24.

A salt having the formula:

• in a crystalline solid form A which provides at least one of:
• (i) an X-ray powder diffraction pattern substantially in accordance with FIG. 25;
• and
• (ii) a DSC scan substantially in accordance with FIG. 29.

A salt having the formula:

• in a crystalline solid form B which provides at least one of:
• (i) an X-ray powder diffraction pattern substantially in accordance with FIG. 30;
• and
• (ii) a TGA scan substantially in accordance with FIG. 31.

A salt having the formula:

• in a crystalline solid form C which provides at least one of:
• (i) an X-ray powder diffraction pattern substantially in accordance with FIG. 32;
• and
• (ii) a DSC scan substantially in accordance with FIG. 34.

A salt having the formula:

• in a crystalline solid form A which provides at least one of:
• (i) an X-ray powder diffraction pattern substantially in accordance with FIG. 37;
• and
• (ii) a DSC scan substantially in accordance with FIG. 43.

A salt having the formula:

• in a crystalline solid form A which provides at least one of:
• (i) an X-ray powder diffraction pattern substantially in accordance with FIG. 44;
• and
• (ii) a DSC scan substantially in accordance with FIG. 48.